Full Press Release Details
SAN FRANCISCO , Oct. 30, 2018 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) will announce its financial results for the third quarter on Wednesday, November 7, 2018 , after the close of U.S.-based financial markets. Howard Robin , president and chief executive officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time (ET)/ 2:00 p.m. Pacific Time (PT).
The press release and a live audio-only Webcast of the conference call can be accessed through a link that is posted on the home page and Investors section of the Nektar website: http://ir.nektar.com/ . The web broadcast of the conference call will be available for replay through Monday, December 10, 2018 .
To access the conference call, follow these instructions:
Dial: (877) 881-2183 (U.S.); (970) 315-0453 (international) Passcode: 9395678 (Nektar Therapeutics is the host)
Nektar Therapeutics is a research-based, development stage biopharmaceutical company whose mission is to discover and develop innovative medicines to address the unmet medical needs of patients. Our R&D pipeline of new investigational medicines includes treatments for cancer, auto-immune disease and chronic pain. We leverage Nektar's proprietary and proven chemistry platform in the discovery and design of our new therapeutic candidates. Nektar is headquartered in San Francisco, California , with additional operations in Huntsville, Alabama and Hyderabad, India . Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com .
For Investors: Jennifer Ruddock of Nektar Therapeutics 415-482-5585
SOURCE Nektar Therapeutics